We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
- Authors
Blackwell, Kimberly L; Burstein, Harold J; Storniolo, Anna Maria; Rugo, Hope S; Sledge, George; Aktan, Gursel; Ellis, Catherine; Florance, Allison; Vukelja, Svetislava; Bischoff, Joachim; Baselga, José; O'Shaughnessy, Joyce
- Abstract
Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall survival (OS) analysis from EGF104900 is reported here.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 21, p2585
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.35.6725